FSA Updates CBD Novel Food Guidance: Clarifies Hemp-Derived Product Status for England & Wales
The UK's Food Standards Agency (FSA) has updated its CBD novel food guidance, clarifying the regulatory status of hemp-derived products and reinforcing pre-market authorisation requirements for England and Wales.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 19 June 2024
The Food Standards Agency (FSA) has reissued its guidance on Cannabidiol (CBD) products classified as novel foods in England and Wales, with a significant update dated 28 August 2026. This revision provides critical clarification regarding the novel food status of various hemp-derived products, a key concern for manufacturers and brand owners operating within the UK market. The updated guidance now includes a dedicated section on 'Consultation requests for novel food status,' explicitly advising businesses to submit requests before marketing new products.
The core of the FSA's clarification distinguishes between 'Hemp-derived non-novel foods' and 'Hemp-derived novel foods,' aiming to reduce ambiguity that previously challenged regulatory compliance. Products derived from hemp that contain CBD and were not substantially consumed in the EU/UK before May 1997 require novel food authorisation. This includes CBD isolates, purified extracts, and many broad/full-spectrum extracts. Conversely, certain parts of the hemp plant, such as seeds or cold-pressed seed oils that do not contain CBD above trace levels, typically fall outside novel food regulations. This distinction mandates a thorough review of existing product formulations and sourcing strategies.
For operators planning new CBD product launches, the requirement to submit a consultation request for novel food status prior to market entry is a critical procedural change. This proactive step is designed to ensure early regulatory alignment, though it also introduces an additional pre-market hurdle and extends time-to-market projections. The FSA maintains a public list of validated novel food applications, serving as a critical reference point for market participants. Businesses must confirm their ingredient's status or initiate the application process to ensure continued market access.
What this means for United Kingdom
UK manufacturers and brand owners of CBD supplements must immediately audit existing product lines against the FSA's updated definitions, particularly those using hemp-derived ingredients. The refined guidance solidifies the requirement for pre-market authorisation for most CBD-containing products, impacting new product development timelines by requiring formal consultation requests before launch. Companies without validated novel food applications for their specific CBD extract face imminent market withdrawal threats post-28 August 2026. This regulatory clarity presents a competitive advantage for compliant businesses, while non-compliance carries significant commercial and reputational risks, including product recall and enforcement actions.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.